BreitbartW, ChandlerS, EagelB, et al.An alternative algorithm for dosing transdermal fentanyl for cancer-related pain. Oncology (Williston Park)2000;14(5):695–705; discussion 705, 709-17.
2.
FuQ, HanN, LiN, Cancer Rehabilitation and Palliative Treatment Professional Committee of Hubei Anti Cancer Association. et al.Guidelines for rational clinical use of fentanyl transdermal patch. Drug Des Devel Ther2024;18:233–255.
3.
DavisM. Fentanyl pharmacokinetic paradoxical in cancer cachexia. J Pain Symptom Manage2024;68(1):e78.
4.
Facts about fentanyl. DEA. n.d. Accessed February 13, 2026.
5.
RoseME. Are prescription opioids driving the opioid crisis? Assumptions vs facts. Pain Med2018;19(4):793–807; doi: 10.1093/pm/pnx048
6.
LowryMF, ChildersJ. Fast Facts and Concepts #484: Opioid diversion risk and management in palliative care. J Palliat Med2024;27(8):1090–1092; doi: 10.1089/jpm.2024.0196
7.
ManettiF, DavidMC, GariglioS, et al.Atypical fentanyl transdermal patch consumption and fatalities: Case report and literature review. Toxics2022;11(1):46; doi: 10.3390/toxics11010046
8.
KuczyńskaK, GrzonkowskiP, KacprzakŁ, et al.Abuse of fentanyl: An emerging problem to face. Forensic Sci Int2018;289:207–214; doi: 10.1016/j.forsciint.2018.05.042
9.
Centers for Disease Control and Prevention. State Unintentional Drug Overdose Reporting System (SUDORS). Final Data. US Department of Health and Human Services, CDC: Atlanta, GA, 2026.
10.
Fentanyl Free America. DEA; 2025. Accessed March 31, 2026.
11.
University of Connecticut Pharmacy. MRI and patch removal characteristics of common transdermal patches. n.d. Accessed February 13, 2026.
12.
GrondS, RadbruchL, LehmannKA. Clinical pharmacokinetics of transdermal opioids: Focus on transdermal fentanyl. Clin Pharmacokinet2000;38(1):59–89; doi: 10.2165/00003088-200038010-00004